Key clinical point: A serum metabolic panel was more effective than prostate-specific antigen at differentiating prostate cancer patients from patients with negative prostate biopsy and healthy controls.
Major finding: The metabolic panel showed a higher diagnostic performance than prostate-specific antigen in distinguishing PCa from control patients, with an area under the curve of 0.823 for the metabolic panel vs. 0.712 for PSA ( P <0.001).
Study details: The data come from a logistic regression analysis of 134 individuals, 39 prostate cancer patients, 45 controls with a negative prostate biopsy, and 50 healthy controls.
Disclosures: The study was funded by the National Natural Science Foundation of China, Science and Technology Support Project in the field of biomedicine of Shanghai Science and Technology Action Plan, Clinical Research Project of Shanghai Municipal Commission of Health and Family Planning, Precision Medicine Program of Second Military Medical University, Youth Startup Program of Second Military Medical University, and Jiangsu Provincial Medical Youth Talent. The researchers had no financial conflicts to disclose.
Source: Xu H et al. Front Oncol. 2021 May 7. doi: 10.3389/fonc.2021.666320.